Net Margin - Prostatype Genomics AB (F:PGO) - Alpha Spread
P

Prostatype Genomics AB
F:PGO

Watchlist Manager
Prostatype Genomics AB
F:PGO
Watchlist
Price: 0.0012 EUR Market Closed
Market Cap: 1.2m EUR
Have any thoughts about
Prostatype Genomics AB?
Write Note

Net Margin
Prostatype Genomics AB

-3 963.1%
Current
-5 323%
Average
-7.7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 963.1%
=
Net Income
-40.5m
/
Revenue
1m

Net Margin Across Competitors

Country SE
Market Cap 18.8m SEK
Net Margin
-3 963%
Country US
Market Cap 341.5B USD
Net Margin
10%
Country US
Market Cap 180.5B USD
Net Margin
10%
Country US
Market Cap 129B USD
Net Margin
32%
Country US
Market Cap 123.6B USD
Net Margin
-5%
Country US
Market Cap 105B USD
Net Margin
4%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 142.3B AUD
Net Margin
18%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country US
Market Cap 38.5B USD
Net Margin
-557%
Country US
Market Cap 35.2B USD
Net Margin
-3%

Profitability Report

View the profitability report to see the full profitability analysis for Prostatype Genomics AB.

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 963.1%
=
Net Income
-40.5m
/
Revenue
1m
What is the Net Margin of Prostatype Genomics AB?

Based on Prostatype Genomics AB's most recent financial statements, the company has Net Margin of -3 963.1%.